Assessment of Serum Fibroblast Growth Factor 21 as a Risk Factor for the Occurrence of Cardiometabolic Disorders among Psoriatic Patients

Abstract

Abstract Background Fibroblast growth factors 21 is a new marker of cardiometabolic disorders which are common comorbidities in psoriasis. Fibroblast growth factor 21 could be useful in predicting the risk of cardiometabolic disorders in psoriatic patients as well as assessment of the impact of phototherapy on serum level of FGF-21 will be done. Aim of the Work The aim of the present work was to evaluate the serum level of FGF-21 in psoriatic patients versus healthy controls and to correlate it with the disease severity (PASI Score), BMI, metabolic parameters and phototherapy. Patients and Methods Assays to measure the level of FGF-21 in serum of 30 Psoriatic patients and 30 healthy adults matched to age, sex and BMI and compare the FGF-21 level between the two groups and after 3 months of treatment the psoriatic patients with NB-UVB sessions. Laboratory investigations including CRP, FBG, Total Cholesterol and serum triglycerides. Results Significantly higher serum levels of FGF-21 in Psoriatic patients compared to the controls. Statistically significant positive correlation between FGF-21 level and severity indices (p < 0.001) denoting its role as severity marker. Statistically positive correlation with CRP (p < 0.001) denoting its role as an activity marker. Conclusion Fibroblast Growth Factor 21 has been described as Psoriatic severity and activity biomarker with prognostic and therapy monitoring applications.